RXRX logo

RXRX
Recursion Pharmaceuticals Inc

14,593
Mkt Cap
$1.75B
Volume
8.62M
52W High
$7.18
52W Low
$2.80
PE Ratio
-2.21
RXRX Fundamentals
Price
$3.28
Prev Close
$3.31
Open
$3.32
50D MA
$3.50
Beta
2.65
Avg. Volume
14.11M
EPS (Annual)
-$1.44
P/B
1.53
Rev/Employee
$124,468.33
$1,160.13
Loading...
Loading...
News
all
press releases
Recursion Pharmaceuticals (RXRX) Stock Declines While Market Improves: Some Information for Investors
Recursion Pharmaceuticals (RXRX) closed at $3.32 in the latest trading session, marking a -2.06% move from the prior day.
Zacks·1d ago
News Placeholder
More News
News Placeholder
Recursion Pharmaceuticals (NASDAQ:RXRX) Director Sells $93,000.00 in Stock
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) Director Blake Borgeson sold 30,000 shares of the firm's stock in a transaction dated Tuesday, April 7th. The shares were sold at an...
MarketBeat·2d ago
News Placeholder
Recursion Pharmaceuticals (RXRX) Beats Stock Market Upswing: What Investors Need to Know
Recursion Pharmaceuticals (RXRX) reached $3.11 at the closing of the latest trading day, reflecting a +1.63% change compared to its last close.
Zacks·8d ago
News Placeholder
Recursion Pharmaceuticals (NASDAQ:RXRX) Rating Lowered to Sell at Wall Street Zen
Wall Street Zen lowered shares of Recursion Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Saturday...
MarketBeat·14d ago
News Placeholder
Here's Why Recursion Pharmaceuticals (RXRX) Fell More Than Broader Market
The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $2.94, representing a -6.67% change from its previous close.
Zacks·14d ago
News Placeholder
Recursion Pharmaceuticals (NASDAQ:RXRX) Reaches New 52-Week Low - What's Next?
Recursion Pharmaceuticals (NASDAQ:RXRX) Reaches New 52-Week Low - Should You Sell...
MarketBeat·15d ago
News Placeholder
Recursion Pharmaceuticals (RXRX) Down 16.5% Since Last Earnings Report: Can It Rebound?
Recursion Pharmaceuticals (RXRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks·15d ago
News Placeholder
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Given Consensus Recommendation of "Hold" by Analysts
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) has received an average rating of "Hold" from the five brokerages that are currently covering the stock, MarketBeat.com reports. One...
MarketBeat·15d ago
News Placeholder
Recursion Pharmaceuticals Details AI-Driven Drug Pipeline, Sanofi/Roche Milestones, Runway to 2028
Recursion Pharmaceuticals (NASDAQ:RXRX) Chief Financial Officer Ben Taylor outlined the company's integrated approach to AI-enabled drug discovery and development, recent portfolio decisions...
MarketBeat·20d ago
News Placeholder
Recursion Pharmaceuticals (RXRX) Advances While Market Declines: Some Information for Investors
In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $3.37, indicating a +1.51% shift from the previous trading day.
Zacks·22d ago
<
1
2
...
>

Latest RXRX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.